Žorž Neža, Poglajen Gregor, Frljak Sabina, Knezevič Ivan, Vrtovec Bojan
Advanced Heart Failure and Transplantation Center, Department of Cardiology, University Medical Center Ljubljana, Ljubljana, Slovenia.
Department of Internal Medicine, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Cell Transplant. 2022 Jan-Dec;31:9636897221080384. doi: 10.1177/09636897221080384.
We investigated the effects of cell therapy on local mechanical dyssynchrony (LMD) in patients with nonischemic dilated cardiomyopathy (NICM). We analyzed electromechanical data of 30 NICM patients undergoing CD34 cell transplantation. All patients underwent bone marrow stimulation; CD34 cells were collected by apheresis and injected transendocardially. At baseline and at 6 months after therapy, we performed electromechanical mapping and measured unipolar voltage (UV) and LMD at cell injection sites. LMD was defined as a temporal difference between global and segmental peak systolic displacement normalized to the average duration of the RR interval. Favorable clinical response was defined as increase in the left ventricular ejection fraction (LVEF) ≥5% between baseline and 6 months. Using paired electromechanical point-by-point analysis, we were able to identify 233 sites of CD34 cell injections in 30 patients. We found no overall differences in local UV between baseline and 6 months (10.7 ± 4.1 mV vs 10.0 ± 3.6 mV, = 0.42). In contrast, LMD decreased significantly (17 ± 17% at baseline vs 13 ± 12% at 6 months, = 0.00007). Favorable clinical response at 6 months was found in 19 (63%) patients (group A), and 11 (37%) patients did not respond to cell therapy (group B). At baseline, the two groups did not differ in age, gender, LVEF, or N terminal-pro brain natriuretic peptide (NT-proBNP) levels. Similarly, we found no differences in baseline UV (9.5 ± 2.9 mV in group A vs 8.6 ± 2.4 mV in group B, = 0.41) or LMD at cell injection sites (17 ± 19% vs 16 ± 14%, = 0.64). In contrast, at 6 months, we found higher UV in group A (10.0 ± 3.1 mV vs 7.4 ± 1.9 mV in group B, = 0.04). Furthermore, when compared with group B, patients in group A displayed a significantly lower LMD (11 ± 12% vs 16 ± 10%, = 0.002). Thus, it appears that favorable clinical effects of cell therapy in NICM patients may be associated with a decrease of LMD at cell injection sites.
我们研究了细胞治疗对非缺血性扩张型心肌病(NICM)患者局部机械性不同步(LMD)的影响。我们分析了30例接受CD34细胞移植的NICM患者的机电数据。所有患者均接受骨髓刺激;通过单采术采集CD34细胞并经心内膜注射。在基线期和治疗后6个月,我们进行了机电标测,并测量了细胞注射部位的单极电压(UV)和LMD。LMD定义为整体和节段性收缩期峰值位移之间的时间差,该时间差经RR间期平均时长标准化。良好的临床反应定义为基线期至6个月期间左心室射血分数(LVEF)增加≥5%。通过配对的逐点机电分析,我们在30例患者中识别出233个CD34细胞注射部位。我们发现基线期和6个月时局部UV无总体差异(10.7±4.1mV对10.0±3.6mV,P=0.42)。相比之下,LMD显著降低(基线期为17±17%,6个月时为13±12%,P=0.00007)。19例(63%)患者在6个月时出现良好的临床反应(A组),11例(37%)患者对细胞治疗无反应(B组)。在基线期,两组在年龄、性别、LVEF或N末端脑钠肽前体(NT-proBNP)水平方面无差异。同样,我们发现基线期UV(A组为9.5±2.9mV,B组为8.6±2.4mV,P=0.41)或细胞注射部位的LMD(17±19%对16±14%,P=0.64)无差异。相比之下,在6个月时,我们发现A组的UV更高(10.0±3.1mV对B组的7.4±1.9mV,P=0.04)。此外,与B组相比,A组患者的LMD显著更低(11±12%对16±10%,P=0.002)。因此,细胞治疗对NICM患者的良好临床效果似乎与细胞注射部位LMD的降低有关。